Cybin Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of psychedelic-based therapeutics for the treatment of mental health disorders. Founded in 2019 and headquartered in Toronto, Canada, the company is pioneering novel drug candidates designed to improve safety and efficacy over naturally occurring psychedelics. Cybin’s research emphasizes proprietary formulations and delivery methods to optimize bioavailability and patient experience.
The company’s pipeline includes multiple investigational products, such as sublingual psilocybin analogs, deuterated tryptamines, and other small-molecule derivatives. These programs target a range of indications including major depressive disorder, anxiety disorders, and substance use disorders. Cybin employs preclinical and clinical studies to evaluate pharmacokinetics, pharmacodynamics, and therapeutic outcomes, with an aim toward advancing its most promising candidates into later-stage trials.
Cybin operates in both Canada and the United States, partnering with academic institutions and contract research organizations to conduct its studies. The company has built a cross-functional team with expertise in medicinal chemistry, clinical development, regulatory affairs, and pharmaceutical manufacturing. Its management team is led by Chief Executive Officer Doug Drysdale and Chief Financial Officer Stephen Schultz, supported by a board with extensive experience in life sciences and healthcare innovation.
Looking ahead, Cybin aims to expand its clinical footprint and engage with regulatory authorities to support potential commercialization pathways. By combining scientific research with novel delivery technologies, the company seeks to address unmet needs in mental healthcare and bring innovative treatment options to patients worldwide.
AI Generated. May Contain Errors.
